SCHEDULE: ARK Investment, Cathie Wood Disclose 12.34% Stake in Pacific Biosciences

ARK Investment Management LLC and Catherine D. Wood have jointly filed an Amendment No. 6 on Schedule 13G, disclosing a combined beneficial ownership of 12.34% in Pacific Biosciences of California, Inc.

Summary

• ARK Investment Management LLC and Catherine D. Wood jointly filed an Amendment No. 6 to Schedule 13G.
• The filing reports their beneficial ownership in Pacific Biosciences of California, Inc. (PBIO).
• They collectively own 37,264,228 shares, representing 12.34% of the common stock.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• ARK Innovation ETF, a series of a Delaware statutory trust, is noted as a client of ARK Investment Management LLC with an interest exceeding 5% in these securities.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant and sustained institutional ownership by a prominent investor like ARK Investment Management can instill confidence in the market regarding the company's long-term potential, even though it's a routine ownership disclosure.

Positives

• Significant institutional ownership by ARK Investment Management LLC and Catherine D. Wood, indicating continued confidence in Pacific Biosciences of California, Inc.
• The explicit statement that shares are held in the ordinary course of business and not for control-influencing purposes suggests a long-term investment perspective.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Pacific Biosciences of California, Inc.'s future performance or operations, as it is solely an ownership disclosure.

Management Comments

• The parties hereto agree to file an Amendment No. 6 on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Amendment No. 6 on Schedule 13G shall be filed on behalf of each of them.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

StockSavvy.ai notes that ARK Investment Management, led by Cathie Wood, is a prominent investor known for its focus on disruptive innovation, particularly in sectors like genomics and biotechnology. Their continued significant stake in Pacific Biosciences of California, Inc. (PBIO), a company specializing in long-read sequencing technology, reinforces their conviction in the growth potential of the genomics industry and PBIO's position within it. This filing indicates a sustained, substantial institutional presence in a key player in the life sciences tools sector.

Comparison to Industry Standards

• ARK Investment Management's 12.34% stake in Pacific Biosciences is a substantial position for an institutional investor, often signaling strong conviction in the company's long-term prospects within the competitive genomics market.
• Compared to other major institutional holders in the biotechnology and life sciences tools sector, a 12.34% stake is a significant concentration, potentially placing PBIO as a core holding within ARK's relevant ETFs, such as the ARK Innovation ETF.
• While specific comparable companies' institutional ownership percentages are not provided in the filing, such a high percentage from a well-known active manager like ARK often draws attention from other investors seeking exposure to high-growth, innovative companies.

Stakeholder Impact

• Shareholders: The continued significant ownership by ARK Investment Management and Catherine D. Wood may be viewed positively, potentially signaling confidence in the company's strategy and future.

Next Steps

• Continue to hold securities in the ordinary course of business.
• File future amendments to Schedule 13G as required by changes in beneficial ownership.

Key Dates

Recommendation

The filing indicates a significant, sustained institutional stake by ARK Investment Management and Catherine D. Wood in Pacific Biosciences. While this signals confidence from a prominent investor, the filing itself is a routine ownership disclosure (Amendment No. 6) and does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It primarily confirms an existing, substantial position, suggesting investors should 'hold' based on this specific information, awaiting further operational updates or changes in investment thesis.

Keywords

Pacific Biosciences, ARK Investment Management, Catherine D. Wood, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, PBIO, Genomics, Biotechnology